A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL)
This study is investigating a new treatment approach for a type of blood cancer called CD30-expressing Peripheral T-cell Lymphoma (PTCL) in adults who haven't received treatment for it yet. The treatment combines a commonly used chemotherapy called CHEP with a targeted medicine called Brentuximab Vedotin, also known as Adcetris. Researchers want to see if this new combination can lead to better outcomes by shrinking the cancer more effectively. They'll be looking carefully at how many people achieve a 'complete response' (meaning the cancer is no longer detectable by certain scans) and also tracking any side effects. This research aims to find safer and more effective ways to treat this specific type of cancer.
At a glance
What is this study about?
This study is like a special investigation into a new way of treating a type of cancer called CD30-expressing Peripheral T-cell Lymphoma (PTCL). PTCL is a cancer that affects certain white blood cells. This particular study is for adults who have this type of cancer but haven't started any treatment for it yet. The main goal is to find out if combining a common chemotherapy treatment (made up of medicines called ETOPOSIDE, DOXORUBICIN, CYCLOPHOSPHAMIDE, and PREDNISONE – which is what 'CHEP' stands for) with a newer targeted medicine called Brentuximab Vedotin (also known as Adcetris) works better than current approaches.
Brentuximab Vedotin (Adcetris) is a medicine designed to target specific cancer cells that have a marker called CD30 on their surface. By adding this targeted medicine to chemotherapy, doctors hope to get a stronger effect against the cancer. The study will pay close attention to how well the cancer shrinks or disappears after treatment, especially looking at scans called PET scans. This is called a 'complete response'. They will also carefully monitor any side effects to understand how safe the new combination is.
By running studies like this, doctors can learn more about how different treatments work and find improved ways to help people with cancer. If this combination treatment proves to be effective and safe, it could become a new option for patients in the future.
Key takeaways
- This study is for adults with a specific, untreated T-cell lymphoma (CD30+ PTCL).
- It combines standard chemotherapy with a targeted drug, Brentuximab Vedotin (Adcetris).
- The main goal is to see how well this new combination shrinks the cancer.
- Researchers will also carefully track any side effects.
- It's a Phase II study, focusing on effectiveness and safety.
- You can stop participating at any time.
Who may be eligible?
This study is looking for adults aged 18 and older. Both men and women can take part. A key requirement is that you must have a specific type of cancer called CD30-expressing Peripheral T-cell Lymphoma (PTCL).
It's also important that you haven't received any treatment for your PTCL before starting the study. This helps researchers understand exactly how the new combination treatment works without other treatments affecting the results.
There might be other health requirements that your doctor will check to make sure the study is a good fit for you and that it's safe for you to participate.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with CD30-expressing Peripheral T-cell Lymphoma (PTCL)?
- Have you *not* received any treatment for your PTCL yet?
- Are you able to commit to regular hospital visits and tests?
What does participation involve?
If you join this study, you will receive a combination of medicines: chemotherapy (ETOPOSIDE, DOXORUBICIN, CYCLOPHOSPHAMIDE, PREDNISONE) and Brentuximab Vedotin (Adcetris) as an infusion. The study involves regular visits to the clinic for your treatments and to have various tests and check-ups. These tests will include blood tests, physical examinations, and scans like PET scans to see how the treatment is affecting your cancer. These assessments will happen during your treatment and for a period afterwards to monitor your health and the long-term effects. The total duration of your participation will depend on the treatment plan and follow-up, which your study doctor will explain in detail.
Potential risks and benefits
Locations (1)
- —UnverifiedCzechia
Common questions
What is a 'Phase II' study?
A Phase II study means researchers are testing if a new treatment is effective against a specific cancer and carefully looking at its side effects in a larger group of patients than in earlier stages.
What is CD30-expressing PTCL?
It's a type of cancer that affects a specific kind of white blood cell called T-cells, and the cancer cells have a particular marker called CD30 on their surface.
What does 'PET-negative complete response' mean?
It means that after treatment, scans called PET scans show no signs of the cancer remaining.
What is Brentuximab Vedotin (Adcetris)?
It's a targeted medicine that attacks cancer cells with the CD30 marker, helping to shrink or kill them.
Will I get a placebo (dummy treatment)?
No, this is an 'open label' study, meaning everyone in the study will receive the active combination treatment.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.